| Summary: | Andrew A Chang,1–3 Thomas Hong,1,2 Shaun Y Ewe,1,2 Bobak Bahrami,1,2 Geoffrey K Broadhead1–3 1Sydney Institute of Vision Science, 2Sydney Retina Clinic and Day Surgery, 3Save Sight Institute, University of Sydney, Sydney, NSW, Australia Abstract: Diabetic macular edema (DME) represents one of the leading causes of visual impairment in working-age adults. Although there are several proven treatments available for this condition, pharmacotherapy through the use of intravitreal antivascular endothelial growth factor agents has revolutionized the management of DME over the past decade with superior outcomes compared to laser therapy. This review summarizes the pathophysiology and available treatment options for the management of DME, with an emphasis on the efficacy and safety profile of a single particular intravitreal antivascular endothelial growth factor agent, aflibercept. Keywords: diabetic macular edema, aflibercept
|
|---|
